Study Details

Back to Search Results

Method of pre-treatment for application of QUTENZA capsaicin 8% patch

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01416116

Astellas Study ID

The unique identification code given by the study sponsor.

QTZ-EC-0002

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2010-023258-34

Follow Trial

Condition

Peripheral Nerve Injury, Nerve Pain from Shingles

Phase

These clinical trials happen after a drug or treatment has been approved for patients to take. Clinical trials in phase 4 usually take place over many years because researchers want to learn about long term use and safety of a drug or treatment.

Phase 4

Age

18 years - 90 years

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jul 2011 - Apr 2012

Masking

Single (Outcomes Assessor)

Enrollment number

122

Tolerability of QUTENZATM when applied after pre-treatment with lidocaine or tramadol in subjects with peripheral neuropathic pain – A randomized, multi-center, assessor-blinded study

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Method of pre-treatment for application of QUTENZA capsaicin 8% patch? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site 201

Prague, Czech Republic

Site 602

Martin, Slovakia

Site 501

Skien, Norway

Site 402

Cork, Ireland

Site 403

Galway, Ireland

Site 101

Roeselare, Belgium

Site 301

Aarhus, Denmark

Site 603

Kosice, Slovakia

Site 103

Genk, Belgium

Site 404

Galway, Ireland

Site 704

Manchester, United Kingdom

Site 502

Hamar, Norway

Site 302

Aalborg, Denmark

Site 203

Olomouc, Czech Republic

Site 703

Solihull, United Kingdom

Site 202

Hradec Králové, Czech Republic

Site 102

Antwerpen, Belgium

Site 702

Glasgow, United Kingdom

Site 701

Liverpool, United Kingdom

Site 601

Bystrica, Slovakia

Site 401

Limerick, Ireland

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo